Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Both DPCP alone and with PRP are effective and safe for treating severe alopecia areata.

Hair regrowth was seen in 83% of children with alopecia, immune system plays a role in the condition, and various treatments showed effectiveness for hair and nail disorders.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Children with alopecia areata should only have thyroid screening if they have Down syndrome, a history of atopy, family history of thyroid disease, or signs of thyroid problems.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Botulinum toxin type A injections are not effective for severe alopecia areata.

Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

HLA-DRB5 and other genes may be linked to alopecia universalis.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Alopecia areata greatly affects people's life quality, mental health, and work life.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

PRP works faster and is a safe alternative to steroids for treating alopecia areata.

Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Some people developed alopecia areata after COVID-19 vaccination, but it's not caused by the vaccine and most improved with treatment.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Yellow dots and short vellus hairs are the most common signs of Alopecia Areata (AA), and trichoscopy can help diagnose AA and track treatment progress.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

The refined wash test is a reliable way to measure daily hair loss and can tell the difference between different types of hair loss.

Patients with alopecia areata may have lower vitamin D levels than healthy people.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.

The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.

Alopecia areata may be linked to heart issues.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.